James Edgemond Sells 7,782 Shares of United Therapeutics Co. (NASDAQ:UTHR) Stock

United Therapeutics Co. (NASDAQ:UTHR) CFO James Edgemond sold 7,782 shares of United Therapeutics stock in a transaction dated Monday, October 21st. The shares were sold at an average price of $366.99, for a total value of $2,855,916.18. Following the completion of the sale, the chief financial officer now owns 6,426 shares of the company’s stock, valued at $2,358,277.74. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

James Edgemond also recently made the following trade(s):

• On Monday, October 14th, James Edgemond sold 7,792 shares of United Therapeutics stock. The shares were sold at an average price of $355.88, for a total transaction of $2,773,016.96.
• On Monday, October 7th, James Edgemond sold 7,794 shares of United Therapeutics stock. The shares were sold at an average price of $355.54, for a total transaction of $2,771,078.76.
• On Monday, September 30th, James Edgemond sold 7,792 shares of United Therapeutics stock. The stock was sold at an average price of $358.62, for a total transaction of $2,794,367.04.
• On Monday, September 23rd, James Edgemond sold 7,796 shares of United Therapeutics stock. The shares were sold at an average price of $354.04, for a total value of $2,760,095.84.
• On Monday, September 9th, James Edgemond sold 7,802 shares of United Therapeutics stock. The stock was sold at an average price of $345.41, for a total value of $2,694,888.82.
• On Tuesday, September 3rd, James Edgemond sold 7,785 shares of United Therapeutics stock. The shares were sold at an average price of $362.37, for a total value of $2,821,050.45.

United Therapeutics Price Performance

Shares of NASDAQ:UTHR opened at $352.58 on Thursday. The company has a current ratio of 4.35, a quick ratio of 4.18 and a debt-to-equity ratio of 0.02. United Therapeutics Co. has a twelve month low of $208.62 and a twelve month high of $377.03. The company’s 50 day moving average is $352.33 and its 200 day moving average is $310.92. The company has a market cap of $15.69 billion, a PE ratio of 16.20, a price-to-earnings-growth ratio of 1.34 and a beta of 0.57.

United Therapeutics (NASDAQ:UTHR) last issued its earnings results on Wednesday, July 31st. The biotechnology company reported $5.85 earnings per share (EPS) for the quarter, missing the consensus estimate of $6.33 by ($0.48). United Therapeutics had a return on equity of 18.82% and a net margin of 40.87%. The business had revenue of $714.90 million for the quarter, compared to analysts’ expectations of $691.87 million. During the same period last year, the business earned $5.24 EPS. The company’s revenue for the quarter was up 19.8% on a year-over-year basis. On average, sell-side analysts forecast that United Therapeutics Co. will post 24.72 EPS for the current year.

Analysts Set New Price Targets

Several analysts have commented on UTHR shares. Jefferies Financial Group increased their price target on shares of United Therapeutics from $315.00 to $432.00 and gave the company a “buy” rating in a research report on Monday, September 23rd. Oppenheimer raised their target price on shares of United Therapeutics from $400.00 to $575.00 and gave the company an “outperform” rating in a research note on Wednesday, August 28th. LADENBURG THALM/SH SH downgraded United Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Thursday, August 1st. Wells Fargo & Company raised their price objective on United Therapeutics from $350.00 to $380.00 and gave the stock an “overweight” rating in a research report on Tuesday, August 20th. Finally, Bank of America reduced their target price on United Therapeutics from $303.00 to $280.00 and set an “underperform” rating on the stock in a research report on Thursday, August 1st. One analyst has rated the stock with a sell rating, three have given a hold rating, ten have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $361.33.

Hedge Funds Weigh In On United Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of the stock. Mediolanum International Funds Ltd raised its position in United Therapeutics by 6.9% during the third quarter. Mediolanum International Funds Ltd now owns 4,804 shares of the biotechnology company’s stock valued at $1,720,000 after acquiring an additional 312 shares in the last quarter. Values First Advisors Inc. purchased a new position in shares of United Therapeutics during the 3rd quarter valued at approximately $90,000. Impact Partnership Wealth LLC acquired a new position in shares of United Therapeutics in the 3rd quarter valued at $254,000. Hennion & Walsh Asset Management Inc. boosted its holdings in United Therapeutics by 31.4% during the third quarter. Hennion & Walsh Asset Management Inc. now owns 4,286 shares of the biotechnology company’s stock worth $1,536,000 after buying an additional 1,023 shares in the last quarter. Finally, First National Bank of Hutchinson boosted its holdings in United Therapeutics by 46.3% during the third quarter. First National Bank of Hutchinson now owns 2,481 shares of the biotechnology company’s stock worth $889,000 after buying an additional 785 shares in the last quarter. Institutional investors and hedge funds own 94.08% of the company’s stock.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.